Moderna-2025-JPM-Presentation_Final-Website

© 2025 Moderna, Inc. All rights reserved.43rdAnnual J.P. Morgan Healthcare ConferenceJanuary 13, 2025© 2025 Moderna, Inc. All rights reserved.This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding:Moderna’s 2025 revenue guidance andfactors impacting the guidance range; the rate of success of Moderna's platform; Moderna's ability to execute on its strategic priorities, including its ability to drive use of Spikevax and mRESVIA, its focus on ten product approvals over the next three years, and its ability to deliver cost efficiency across the business to breakeven in 2028; the size and durability of the COVID-19 and RSV markets, as well as markets for potential future products; and the potential and timing for future product approvals, data readouts and commercial launches. The forward-looking statements in this presentation are neither promises nor guarantees, and you sh